Bill > HB1062

This bill establishes new requirements for state employee health plans, accident and sickness insurance policies, and health maintenance organizations (HMOs) regarding prescription drug coverage for advanced, metastatic cancer and associated conditions. Specifically, the bill prohibits these health plans from requiring patients to first fail or prove a history of failure with a different prescription drug before covering a new prescription drug. The bill applies only to prescription drugs that are consistent with best practices for treating advanced, metastatic cancer, supported by peer-reviewed evidence-based literature, and approved by the FDA. "Advanced, metastatic cancer" is defined as cancer that has spread from its original site to other body parts, while "associated conditions" are symptoms or side effects that could further harm the patient's health if left untreated. The provisions will take effect on July 1, 2025, and apply to state employee health plans, individual and group insurance policies, and HMOs that provide prescription drug coverage for advanced, metastatic cancer. The goal is to give patients and healthcare providers more flexibility in choosing appropriate cancer treatments without being constrained by step therapy or prior authorization requirements.

Business and Industry

https://iga.in.gov/legislative/2025/bills/house/1062/details